Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1475273 | 0.90 | KCNH2 (0.33) | EGLN1KCNH2TDP1CYP2D6CYP2C19 | |
| SCHEMBL1476211 | 0.86 | EGLN1 (0.36) | EGLN1EGLN3TDP1CYP2D6CYP2C19 | |
| SCHEMBL1475173 | 0.85 | PIM1 (0.37) | EGLN1EGLN3TDP1CYP2D6CYP2C19 | |
| SCHEMBL1475797 | 0.79 | EGLN1 (0.38) | EGLN1EGLN3 | |
| SCHEMBL1475470 | 0.78 | EGLN1 (0.33) | EGLN1KCNH2OPRM1 | |
| SCHEMBL1476774 | 0.76 | EGLN1 (0.40) | EGLN1KCNH2CYP2D6 | |
| SCHEMBL12827746 | 0.76 | OPRL1 (0.41) | EGLN1EGLN3OPRM1 | |
| SCHEMBL1475315 | 0.75 | EGLN1 (0.35) | EGLN1CYP2D6CYP2C19 | |
| SCHEMBL1475254 | 0.75 | PIM1 (0.35) | EGLN1KCNH2CYP2D6CYP2C19 | |
| SCHEMBL1475575 | 0.75 | DRD2 (0.35) | EGLN1KCNH2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915274-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915274-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915274-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | EGLN1 175/4885KCNH2 451/4885EGLN3 169/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | EGLN1 220/4885KCNH2 762/4885EGLN3 531/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | EGLN1 175/4885KCNH2 451/4885EGLN3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.